GAITHERSBURG, Md., June 1, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the Jefferies Global Healthcare Conference.
Conference Details: | ||||||
Fireside Chat | ||||||
Date: | Thursday, June 8, 2023 | |||||
Time: | 9:00 – 9:25 a.m. Eastern Daylight Time (EDT) | |||||
Location: | New York, NY | |||||
Moderator: | Roger Song, M.D., CFA, Equity Research Analyst – Biotechnology | |||||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research and Development | |||||
Conference | ||||||
Event: | Investor Meetings | |||||
Date: | Thursday, June 8, 2023 | |||||
Recordings
A replay of the recorded fireside session will be available through the Events and Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza, and COVID and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-709-5563
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.45 |
| Daily Change: | 0.46 6.58 |
| Daily Volume: | 7,329,094 |
| Market Cap: | US$1.190B |
May 19, 2025 April 29, 2025 April 15, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
